Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies the effects of hyperthermic intraperitoneal chemotherapy (HIPEC) in treating patients with pancreatic cancer that has spread to the internal abdominal area (peritoneal metastasis). Chemotherapy drugs, such as mitomycin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. HIPEC involves "heated" chemotherapy that is placed directly in the abdomen through laparoscopic instruments, instead of through an intravenous injection. This study may help doctors determine how safe and effective HIPEC work in treating patient with pancreatic cancer.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To assess short-term morbidity and disease-free survival outcomes for patients with pancreatic adenocarcinoma with limited low volume peritoneal metastasis or positive peritoneal cytology undergoing hyperthermic intraperitoneal chemotherapy. SECONDARY OBJECTIVE: I. To evaluate the efficacy of a polymerase chain reaction (PCR)-based quantitative cell-free deoxyribonucleic acid (DNA) KRAS mutation assay in identifying patients at risk of peritoneal recurrence/progression. OUTLINE: Patients undergo HIPEC with mitomycin and cisplatin over 60 minutes in the absence of disease progression or unacceptable toxicity. Patients may undergo additional HIPEC with mitomycin and cisplatin up to 5 times. After completion of study treatment, patients are followed up every 6 months. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04858009
Study type Interventional
Source Mayo Clinic
Status Not yet recruiting
Phase Phase 2
Start date May 15, 2021
Completion date May 31, 2026

See also
  Status Clinical Trial Phase
Withdrawn NCT03925428 - Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas Phase 1
Recruiting NCT04524702 - Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer Phase 2
Recruiting NCT04132505 - Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer Phase 1
Recruiting NCT04390243 - Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation Phase 2
Active, not recruiting NCT03723915 - Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer Phase 2
Completed NCT03291938 - IACS-010759 in Advanced Cancers Phase 1
Not yet recruiting NCT04673448 - Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer Phase 1
Recruiting NCT03816358 - Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer Phase 1/Phase 2
Active, not recruiting NCT02983578 - Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer Phase 2
Recruiting NCT04067960 - Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer
Not yet recruiting NCT04821284 - Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT04233866 - Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread Phase 2
Not yet recruiting NCT04158635 - Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer Phase 1
Withdrawn NCT03432676 - Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer Phase 2
Recruiting NCT03784677 - SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors Phase 1
Not yet recruiting NCT04387071 - CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma Phase 1/Phase 2
Recruiting NCT03608631 - iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation Phase 1
Recruiting NCT04191421 - Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT04837118 - Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study N/A
Not yet recruiting NCT04514497 - Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer Phase 1